You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHaloperidol
Accession NumberDB00502  (APRD00538)
TypeSmall Molecule
GroupsApproved
Description

A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279)

Structure
Thumb
Synonyms
1-(3-P-Fluorobenzoylpropyl)-4-P-chlorophenyl-4-hydroxypiperidine
4-(4-(Para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
4'-Fluoro-4-(4-(P-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
gamma-(4-(P-Chlorophenyl)-4-hydroxpiperidino)-P-fluorbutyrophenone
Haldol
Haloperidolum
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Haldolinjection5 mg/mLintramuscularJanssen Pharmaceuticals, Inc.1971-05-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haldol Decanoateinjection100 mg/mLintramuscularJanssen Pharmaceuticals, Inc.1986-01-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haldol Decanoateinjection50 mg/mLintramuscularJanssen Pharmaceuticals, Inc.1986-01-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haldol Injection 5mg/mlliquid5 mgintramuscularMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1966-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haldol LA Inj 100mg/mlliquid100 mgintramuscularJanssen Inc1983-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haldol LA Inj 50mg/mlliquid50 mgintramuscularJanssen Inc1983-12-312006-01-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidolinjection5 mg/mLintramuscularPatriot Pharmaceuticals LLC2011-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection5 mg/mLintramuscularTYA Pharmaceuticals2011-06-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection5 mg/1intramuscularREMEDYREPACK INC.2013-04-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection100 mg/mLintramuscularPatriot Pharmaceuticals LLC2011-06-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection50 mg/mLintramuscularPatriot Pharmaceuticals LLC2011-06-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoate Inj. Liq Im 100mg/mlliquid100 mgintramuscularDavid Bull Laboratories (Pty) Ltd.1995-12-311998-08-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Decanoate Inj. Liq Im 50mg/mlliquid50 mgintramuscularDavid Bull Laboratories (Pty) Ltd.1995-12-311998-08-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Decanoate Injectionliquid100 mgintramuscularHospira Healthcare CorporationNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Decanoate Injectionliquid50 mgintramuscularHospira Healthcare CorporationNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Decanoate Injectionsolution100 mgintramuscularMylan Pharmaceuticals UlcNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Decanoate Injectionsolution50 mgintramuscularMylan Pharmaceuticals UlcNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Inj 5mg/ml USPliquid5 mgintramuscularSandoz Canada Incorporated1989-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Injectionsolution5 mgintramuscularOmega Laboratories Ltd2011-09-19Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Injection, USPsolution5 mgintramuscularFresenius Kabi Canada Ltd2014-10-20Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol LAliquid100 mgintramuscularSandoz Canada Incorporated1994-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol LAliquid50 mgintramuscularSandoz Canada Incorporated1994-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Long Actingliquid100 mgintramuscularNovopharm Limited2001-08-022005-08-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Long Actingliquid50 mgintramuscularNovopharm Limited2001-08-022005-08-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Tab 0.5mgtablet.5 mgoralPro Doc Limitee1983-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Tab 1mgtablet1 mgoralPro Doc Limitee1983-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Tab 2mgtablet2 mgoralPro Doc Limitee1988-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol Tab 5mgtablet5 mgoralPro Doc Limitee1988-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol-10 Tab 10mgtablet10 mgoralPro Doc Limitee1988-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol-LA Omegaliquid50 mgintramuscularOmega Laboratories Ltd1999-06-30Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidol-LA Omegaliquid100 mgintramuscularOmega Laboratories Ltd1999-05-28Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-peridoltablet1 mgoralTeva Canada Limited1986-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-peridoltablet5 mgoralTeva Canada Limited1984-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-peridoltablet20 mgoralTeva Canada Limited1988-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-peridoltablet10 mgoralTeva Canada Limited1986-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-peridoltablet0.5 mgoralTeva Canada Limited1986-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-peridoltablet2 mgoralTeva Canada Limited1986-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-peridol Oral Soln 2mg/mlsolution2 mgoralNovopharm Limited1987-12-312005-08-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-haloperidoltablet10 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-haloperidoltablet1 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-haloperidoltablet0.5 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-haloperidoltablet5 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-haloperidoltablet2 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-haloperidol Soln 2mg/mlsolution2 mgoralPharmascience Inc1988-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-haloperidol-LAliquid100 mgintramuscularPharmascience Inc1997-08-17Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-haloperidol-LAliquid50 mgintramuscularPharmascience Inc1997-09-24Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-haloperidol 2mg/mlsolution2 mgoralRatiopharm Inc Division Of Teva Canada Limited1982-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-haloperidol Tab 0.5mgtablet.5 mgoralRatiopharm Inc Division Of Teva Canada Limited1982-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-haloperidol Tab 10mgtablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited1987-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-haloperidol Tab 1mgtablet1 mgoralRatiopharm Inc Division Of Teva Canada Limited1982-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-haloperidol Tab 2mgtablet2 mgoralRatiopharm Inc Division Of Teva Canada Limited1987-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-haloperidol Tab 5mgtablet5 mgoralRatiopharm Inc Division Of Teva Canada Limited1985-12-312006-08-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rho-haloperidol Decanoate Inj.-im 100mg/mlsolution100 mgintramuscularRhodiapharm Inc1997-05-072005-08-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rho-haloperidol Decanoate Inj.-im 50mg/mlsolution50 mgintramuscularRhodiapharm Inc1997-05-072005-08-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Haloperidol Liq 2mg/mlliquid2 mgoralApotex Inc1983-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo Haloperidol Tab 0.5mgtablet.5 mgoralApotex Inc1980-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo Haloperidol Tab 1mgtablet1 mgoralApotex Inc1980-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-haloperidol LA Injectableliquid100 mgintramuscularApotex Inc2000-06-302013-08-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-haloperidol LA Injectableliquid50 mgintramuscularApotex Inc2000-06-302013-08-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-haloperidol Tab 10mgtablet10 mgoralApotex Inc1987-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-haloperidol Tab 2mgtablet2 mgoralApotex Inc1987-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-haloperidol Tab 5mgtablet5 mgoralApotex Inc1987-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Haloperidolinjection, solution5 mg/mLintramuscularSagent Pharmaceuticals2011-10-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralAmerican Health Packaging2008-03-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralCardinal Health2004-02-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection, solution5 mg/mLintramuscularPfizer Laboratories Div Pfizer Inc2011-05-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet.5 mg/1oralCardinal Health2012-09-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet20 mg/1oralMylan Pharmaceuticals Inc.2009-07-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralSandoz Inc1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet.5 mg/1oralMylan Institutional Inc.2004-02-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralClinical Solutions Wholesale1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-03-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralRebel Distributors Corp1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection5 mg/mLintramuscularCardinal Health2001-06-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralCardinal Health2012-09-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralMylan Pharmaceuticals Inc.2009-07-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralSandoz Inc1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralMylan Institutional Inc.2009-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralTYA Pharmaceuticals1986-06-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralMc Kesson Contract Packaging2013-04-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralMajor Pharmaceuticals2015-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet.5 mg/1oralPhysicians Total Care, Inc.1999-04-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet.5 mg/1oralREMEDYREPACK INC.2014-05-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralClinical Solutions Wholesale1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralSandoz Inc1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection, solution5 mg/mLintramuscularREMEDYREPACK INC.2013-06-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralTYA Pharmaceuticals1986-06-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet20 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralCardinal Health2012-09-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralMajor Pharmaceuticals2009-02-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralPhysicians Total Care, Inc.1996-10-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralREMEDYREPACK INC.2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet.5 mg/1oralClinical Solutions Wholesale1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet.5 mg/1oralSandoz Inc1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralREMEDYREPACK INC.2011-10-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralTYA Pharmaceuticals2008-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralCardinal Health1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralMajor Pharmaceuticals2009-02-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralPhysicians Total Care, Inc.1995-07-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet20 mg/1oralREMEDYREPACK INC.2013-02-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralContract Pharmacy Services Pa2010-07-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralLake Erie Medical DBA Quality Care Products LLC1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection5 mg/mLintramuscularTeva Parenteral Medicines, Inc.2002-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralREMEDYREPACK INC.2011-09-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection, solution5 mg/mLintramuscularFresenius Kabi USA, LLC2000-10-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralCardinal Health1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralMajor Pharmaceuticals2009-02-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolsolution2 mg/mLoralSilarx Pharmaceuticals, Inc2009-09-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralMylan Institutional Inc.2004-02-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet20 mg/1oralCadila Healthcare Limited2008-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection, solution5 mg/mLintramuscularCardinal Health2010-12-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolsolution, concentrate2 mg/mLoralPharmaceutical Associates, Inc.2009-11-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection5 mg/mLintramuscularTeva Parenteral Medicines, Inc.2002-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralPd Rx Pharmaceuticals, Inc.1986-06-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralDispensing Solutions, Inc.1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralCardinal Health1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralMylan Institutional Inc.2004-02-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralCadila Healthcare Limited2008-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolsolution2 mg/mLoralQualitest Pharmaceuticals1993-09-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet20 mg/1oralSandoz Inc1988-03-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralClinical Solutions Wholesale1988-03-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet2 mg/1oralREMEDYREPACK INC.2010-12-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection, solution5 mg/mLintramuscularCardinal Health2011-05-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection, solution5 mg/mLintramuscularSagent Pharmaceuticals2011-10-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet20 mg/1oralAmerican Health Packaging2008-04-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet.5 mg/1oralCardinal Health1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolsolution, concentrate2 mg/mLoralTeva Pharmaceuticals USA Inc1988-12-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralCadila Healthcare Limited2008-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralCardinal Health1986-06-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet.5 mg/1oralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet10 mg/1oralSandoz Inc1988-03-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet1 mg/1oralMylan Institutional Inc.2004-02-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralClinical Solutions Wholesale1986-11-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidoltablet5 mg/1oralREMEDYREPACK INC.2010-12-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection5 mg/mLintramuscularCardinal Health2001-08-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidolinjection5 mg/mLintramuscularGeneral Injectables and Vaccines, Inc2014-09-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection100 mg/mLintramuscularTeva Parenteral Medicines, Inc.1999-06-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection50 mg/mLintramuscularAmneal Agila, Llc2013-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection100 mg/mLintramuscularTYA Pharmaceuticals2000-07-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection100 mg/mLintramuscularMylan Institutional LLC2013-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection50 mg/mLintramuscularMylan Institutional LLC2013-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection100 mg/mLintramuscularMylan Institutional LLC2013-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection100 mg/mLintramuscularAmneal Agila, Llc2013-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection100 mg/mLintramuscularFresenius Kabi USA, LLC2000-07-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection50 mg/mLintramuscularTeva Parenteral Medicines, Inc.1999-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection50 mg/mLintramuscularAmneal Agila, Llc2013-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection50 mg/mLintramuscularFresenius Kabi USA, LLC2000-02-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection100 mg/mLintramuscularTeva Parenteral Medicines, Inc.1999-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection100 mg/mLintramuscularAmneal Agila, Llc2013-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection50 mg/mLintramuscularTeva Parenteral Medicines, Inc.1999-06-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Decanoateinjection50 mg/mLintramuscularMylan Institutional LLC2013-04-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Lactateinjection5 mg/mLintramuscularGENERAL INJECTABLES AND VACCINES, INC.2015-10-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Lactateinjection, solution5 mg/mLintramuscularCardinal Health2011-05-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Haloperidol Lactateinjection, solution5 mg/mLintramuscularMylan Institutional LLC2011-05-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AloperidinJanssen-Cilag
BioperidoloFirma
BrotoponPfizer
DozicRosemont
DuraperidolNot Available
Einalon SNot Available
EukystolMerckle
HalostenShionogi Seiyaku
KeselanSumitomo
LintonTanabe Mitsubishi Pharma
Peluceslsei
SerenacePfizer
SigaperidolSiegfried
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Haloperidol decanoate
ThumbNot applicableDBSALT001195
Haloperidol lactate
ThumbNot applicableDBSALT001232
Categories
CAS number52-86-8
WeightAverage: 375.864
Monoisotopic: 375.140134897
Chemical FormulaC21H23ClFNO2
InChI KeyInChIKey=LNEPOXFFQSENCJ-UHFFFAOYSA-N
InChI
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
IUPAC Name
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
SMILES
OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Phenylbutylamine
  • Butyrophenone
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzoyl
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Chlorobenzene
  • Benzenoid
  • Gamma-aminoketone
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of psychotic disorders (eg. schizophrenia) and delirium, as well as to control tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome). Also used for the treatment of severe behavioural problems in children with disrubtive behaviour disorder or ADHD (attention-deficit hyperactivity disorder). Haloperidol has been used in the prevention and control of severe nausea and vomiting.
PharmacodynamicsHaloperidol is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.
Mechanism of actionThe precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ.
AbsorptionOral-60%
Volume of distributionNot Available
Protein binding92%
Metabolism

Hepatic

SubstrateEnzymesProduct
Haloperidol
4-(4-chlorophenyl)-4-hydroxypiperidineDetails
Haloperidol
Reduced haloperidolDetails
Haloperidol
Haloperidol glucuronideDetails
Haloperidol
Haloperidol 1,2,3,6-tetrahydropyridineDetails
Haloperidol
fluorobenzoylpropionic acidDetails
Haloperidol
4-(4-Chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-pyridinium (HPP+)Details
Reduced haloperidol
Not Available
Haloperidol reduced pyridinium ion derivativeDetails
Haloperidol reduced pyridinium ion derivative
Haloperidol pyridinium ion derivativeDetails
Haloperidol 1,2,3,6-tetrahydropyridine
Not Available
Haloperidol pyridinium ion derivativeDetails
Route of eliminationNot Available
Half life3 weeks
ClearanceNot Available
ToxicityLD50=165 mg/kg (rats, oral)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9465
Caco-2 permeable+0.6023
P-glycoprotein substrateSubstrate0.6673
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8137
Renal organic cation transporterInhibitor0.6058
CYP450 2C9 substrateNon-substrate0.8355
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.5796
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9207
CYP450 2D6 inhibitorInhibitor0.9197
CYP450 2C19 inhibitorNon-inhibitor0.9248
CYP450 3A4 inhibitorInhibitor0.6899
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7933
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8769
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.4367 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5
hERG inhibition (predictor II)Inhibitor0.7474
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil pharmaceutical
  • Ortho mcneil pharmaceutical inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Purepac pharmaceutical co
  • Quantum pharmics ltd
  • Roxane laboratories inc
  • Royce laboratories inc
  • Sandoz inc
  • Scs pharmaceuticals
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Ortho mcneil janssen pharmaceutical inc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Alpharma uspd inc
  • Morton grove pharmaceuticals inc
  • Pharmaceutical assoc inc div beach products
  • Silarx pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Ortho mcneil janssen pharmaceuticals inc
  • Abraxis pharmaceutical products
  • Akorn strides llc
  • Gland pharma ltd
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Solopak laboratories inc
  • Actavis mid atlantic llc
Packagers
Dosage forms
FormRouteStrength
Liquidoral2 mg
Tabletoral.5 mg
Tabletoral1 mg
Injectionintramuscular5 mg/1
Injectionintramuscular5 mg/mL
Injection, solutionintramuscular5 mg/mL
Solutionoral2 mg/mL
Solution, concentrateoral2 mg/mL
Tabletoral.5 mg/1
Tabletoral1 mg/1
Tabletoral10 mg/1
Tabletoral2 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Injectionintramuscular100 mg/mL
Injectionintramuscular50 mg/mL
Liquidintramuscular5 mg
Solutionintramuscular5 mg
Liquidintramuscular100 mg
Liquidintramuscular50 mg
Tabletoral0.5 mg
Tabletoral10 mg
Tabletoral2 mg
Tabletoral20 mg
Tabletoral5 mg
Solutionoral2 mg
Solutionintramuscular100 mg
Solutionintramuscular50 mg
Prices
Unit descriptionCostUnit
Haloperidol Decanoate 100 mg/ml Solution 5ml Vial257.14USD vial
Haldol decanoate 100 ampul107.77USD ml
Haldol decanoate 50 ampul56.53USD ml
Haloperidol dec 100 mg/ml vial29.85USD ml
Haloperidol powder21.42USD g
Haloperidol dec 50 mg/ml vial17.71USD ml
Haloperidol La 100 mg/ml15.42USD ml
Haldol 5 mg/ml ampul13.4USD ml
Haloperidol La 50 mg/ml7.71USD ml
Haloperidol 5 mg/ml4.73USD ml
Haloperidol lac 5 mg/ml vial3.54USD ml
Haloperidol 20 mg tablet2.81USD tablet
Haloperidol 10 mg tablet1.46USD tablet
Haloperidol 5 mg tablet0.8USD tablet
Novo-Peridol 20 mg Tablet0.66USD tablet
Haloperidol 2 mg tablet0.49USD tablet
Haloperidol lac 2 mg/ml conc0.45USD ml
Haloperidol 1 mg tablet0.36USD tablet
Haloperidol 0.5 mg tablet0.25USD tablet
Pernox scrub cleanser0.18USD g
Apo-Haloperidol 5 mg Tablet0.16USD tablet
Novo-Peridol 5 mg Tablet0.16USD tablet
Apo-Haloperidol 10 mg Tablet0.14USD tablet
Novo-Peridol 10 mg Tablet0.14USD tablet
Apo-Haloperidol 2 mg Tablet0.11USD tablet
Novo-Peridol 2 mg Tablet0.11USD tablet
Apo-Haloperidol 1 mg Tablet0.06USD tablet
Novo-Peridol 1 mg Tablet0.06USD tablet
Apo-Haloperidol 0.5 mg Tablet0.04USD tablet
Novo-Peridol 0.5 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point151.5 °CPhysProp
water solubility14 mg/L (at 25 °C)MERCK INDEX (1996)
logP4.30EL TAYAR,N ET AL. (1985)
logS-4.43ADME Research, USCD
pKa8.66EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.00446 mg/mLALOGPS
logP3.7ALOGPS
logP3.66ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)13.96ChemAxon
pKa (Strongest Basic)8.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity102.59 m3·mol-1ChemAxon
Polarizability39.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-baz0000000-cc6a990404ba7b9452a8View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

DrugSyn.org

US3438991
General References
  1. Niemegeers CJ, Laduron PM: Pharmacology and biochemistry of haloperidol. Proc R Soc Med. 1976;69 suppl 1:3-8. Pubmed
External Links
ATC CodesN05AD01
AHFS Codes
  • 28:16.08.08
PDB EntriesNot Available
FDA labelDownload (169 KB)
MSDSDownload (73.2 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Haloperidol can be increased when it is combined with Abiraterone.
AclidiniumAclidinium may increase the anticholinergic activities of Haloperidol.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Haloperidol.
AmisulprideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Haloperidol.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Haloperidol.
AmphetamineHaloperidol may decrease the stimulatory activities of Amphetamine.
AprepitantThe serum concentration of Haloperidol can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Haloperidol.
AzelastineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Haloperidol.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Haloperidol.
BenzphetamineHaloperidol may decrease the stimulatory activities of Benzphetamine.
BexaroteneThe serum concentration of Haloperidol can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Haloperidol can be decreased when it is combined with Bosentan.
Botulinum Toxin Type AHaloperidol may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BHaloperidol may increase the anticholinergic activities of Botulinum Toxin Type B.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Haloperidol.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
BromocriptineThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Bromocriptine.
BuprenorphineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Haloperidol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Haloperidol.
CarbamazepineThe metabolism of Haloperidol can be increased when combined with Carbamazepine.
CathinoneHaloperidol may decrease the stimulatory activities of Cathinone.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Haloperidol.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Haloperidol.
Cimetropium BromideHaloperidol may increase the anticholinergic activities of Cimetropium Bromide.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Haloperidol.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Haloperidol.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Haloperidol.
ConivaptanThe serum concentration of Haloperidol can be increased when it is combined with Conivaptan.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Haloperidol.
DabrafenibThe serum concentration of Haloperidol can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Haloperidol can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Haloperidol can be decreased when it is combined with Deferasirox.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Haloperidol.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Haloperidol.
DextroamphetamineHaloperidol may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Haloperidol.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Haloperidol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Haloperidol.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Haloperidol.
DofetilideHaloperidol may increase the QTc-prolonging activities of Dofetilide.
DonepezilDonepezil may increase the central neurotoxic activities of Haloperidol.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Haloperidol.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Haloperidol.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Haloperidol.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Haloperidol.
EluxadolineHaloperidol may increase the activities of Eluxadoline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Haloperidol.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Haloperidol.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Haloperidol.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Haloperidol.
EthanolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Haloperidol.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Haloperidol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Haloperidol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Haloperidol.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Haloperidol.
FluconazoleThe metabolism of Haloperidol can be decreased when combined with Fluconazole.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Haloperidol.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Haloperidol.
FluvoxamineThe serum concentration of Haloperidol can be increased when it is combined with Fluvoxamine.
FosaprepitantThe serum concentration of Haloperidol can be increased when it is combined with Fosaprepitant.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Haloperidol.
Fusidic AcidThe serum concentration of Haloperidol can be increased when it is combined with Fusidic Acid.
GalantamineGalantamine may increase the central neurotoxic activities of Haloperidol.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Haloperidol is combined with Glucagon recombinant.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Haloperidol.
GlycopyrrolateThe serum concentration of Haloperidol can be decreased when it is combined with Glycopyrrolate.
GoserelinGoserelin may increase the QTc-prolonging activities of Haloperidol.
HydrocodoneHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Haloperidol.
IdelalisibThe serum concentration of Haloperidol can be increased when it is combined with Idelalisib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Haloperidol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Haloperidol.
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Haloperidol.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Haloperidol.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Haloperidol.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Haloperidol.
IvabradineIvabradine may increase the QTc-prolonging activities of Haloperidol.
IvacaftorThe serum concentration of Haloperidol can be increased when it is combined with Ivacaftor.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Haloperidol.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Haloperidol.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Haloperidol.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Haloperidol.
LisdexamfetamineHaloperidol may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Haloperidol.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Haloperidol.
LuliconazoleThe serum concentration of Haloperidol can be increased when it is combined with Luliconazole.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Haloperidol.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Haloperidol.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Haloperidol.
MequitazineHaloperidol may increase the arrhythmogenic activities of Mequitazine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Haloperidol.
MethamphetamineHaloperidol may decrease the stimulatory activities of Methamphetamine.
MethotrimeprazineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethylphenidateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Haloperidol.
MetyrosineHaloperidol may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Haloperidol.
MifepristoneMifepristone may increase the QTc-prolonging activities of Haloperidol.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Haloperidol.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
MirabegronThe risk or severity of adverse effects can be increased when Haloperidol is combined with Mirabegron.
MirtazapineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MitotaneThe serum concentration of Haloperidol can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Haloperidol.
MorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Haloperidol.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Haloperidol.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Haloperidol.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Haloperidol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Haloperidol.
NelfinavirThe metabolism of Haloperidol can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Haloperidol can be increased when it is combined with Netupitant.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Haloperidol.
OctreotideOctreotide may increase the QTc-prolonging activities of Haloperidol.
OrphenadrineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.
PalbociclibThe serum concentration of Haloperidol can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Haloperidol can be increased when it is combined with Panobinostat.
ParaldehydeHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Haloperidol.
PhendimetrazineHaloperidol may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Haloperidol.
PhentermineHaloperidol may decrease the stimulatory activities of Phentermine.
PhenytoinThe metabolism of Haloperidol can be increased when combined with Phenytoin.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.
Potassium ChlorideHaloperidol may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Haloperidol.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Haloperidol.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Haloperidol.
PromazinePromazine may increase the QTc-prolonging activities of Haloperidol.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Haloperidol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Haloperidol.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Haloperidol.
QuinidineHaloperidol may increase the QTc-prolonging activities of Quinidine.
RamosetronHaloperidol may increase the activities of Ramosetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Haloperidol.
RitonavirThe metabolism of Haloperidol can be decreased when combined with Ritonavir.
RivastigmineRivastigmine may increase the central neurotoxic activities of Haloperidol.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Haloperidol.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Haloperidol.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Haloperidol.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Haloperidol.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Haloperidol.
SiltuximabThe serum concentration of Haloperidol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Haloperidol can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Haloperidol.
St. John's WortThe serum concentration of Haloperidol can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Haloperidol can be increased when it is combined with Stiripentol.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Haloperidol.
SulpirideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Haloperidol.
SuvorexantHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Tacrine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Haloperidol resulting in a loss in efficacy.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Haloperidol.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Haloperidol.
ThalidomideHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Haloperidol.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Haloperidol.
TiclopidineThe metabolism of Haloperidol can be decreased when combined with Ticlopidine.
TiotropiumHaloperidol may increase the anticholinergic activities of Tiotropium.
TocilizumabThe serum concentration of Haloperidol can be decreased when it is combined with Tocilizumab.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Haloperidol.
TopiramateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Topiramate.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Haloperidol.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Haloperidol.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Haloperidol.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Haloperidol.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Haloperidol.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Haloperidol.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Haloperidol.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Haloperidol.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Haloperidol.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Haloperidol.
ZolpidemHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Take with food to reduce irritation, limit caffeine intake. Avoid alcohol.

Targets

1. D(2) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
D(2) dopamine receptor P14416 Details

References:

  1. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, Cox BF, Brioni JD, Moreland RB: Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005 May;81(1):211-9. Pubmed
  2. Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore GJ, Bolognani F, Lauriello J, Perrone-Bizzozero N, Galloway MP: Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology. 2006 Apr;31(4):751-6. Pubmed
  3. Ishiwata K, Oda K, Sakata M, Kimura Y, Kawamura K, Oda K, Sasaki T, Naganawa M, Chihara K, Okubo Y, Ishii K: A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors. Ann Nucl Med. 2006 Oct;20(8):569-73. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  5. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. Pubmed
  6. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. Pubmed
  7. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. Pubmed
  8. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. Pubmed

2. Glutamate receptor ionotropic, NMDA 2B

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Glutamate receptor ionotropic, NMDA 2B Q13224 Details

References:

  1. Hattori K, Uchino S, Isosaka T, Maekawa M, Iyo M, Sato T, Kohsaka S, Yagi T, Yuasa S: Fyn is required for haloperidol-induced catalepsy in mice. J Biol Chem. 2006 Mar 17;281(11):7129-35. Epub 2006 Jan 10. Pubmed
  2. Zhuravliova E, Barbakadze T, Natsvlishvili N, Mikeladze DG: Haloperidol induces neurotoxicity by the NMDA receptor downstream signaling pathway, alternative from glutamate excitotoxicity. Neurochem Int. 2007 Jun;50(7-8):976-82. Epub 2006 Nov 7. Pubmed
  3. Gu WH, Yang S, Shi WX, Zhen XC, Jin GZ: Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine. Acta Pharmacol Sin. 2007 Jul;28(7):953-8. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  5. Steinmetz RD, Fava E, Nicotera P, Steinhilber D: A simple cell line based in vitro test system for N-methyl-D-aspartate (NMDA) receptor ligands. J Neurosci Methods. 2002 Jan 15;113(1):99-110. Pubmed
  6. Sinor JD, Du S, Venneti S, Blitzblau RC, Leszkiewicz DN, Rosenberg PA, Aizenman E: NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro. J Neurosci. 2000 Dec 1;20(23):8831-7. Pubmed
  7. Gallagher MJ, Huang H, Lynch DR: Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions. J Neurochem. 1998 May;70(5):2120-8. Pubmed

3. D(1A) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
D(1A) dopamine receptor P21728 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. Pubmed

4. 5-hydroxytryptamine receptor 2A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: other/unknown

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2A P28223 Details

References:

  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. Pubmed

5. D(3) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inverse agonist

Components

Name UniProt ID Details
D(3) dopamine receptor P35462 Details

References:

  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. Pubmed
  2. Tuppurainen H, Kuikka JT, Viinamaki H, Husso M, Tiihonen J: Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin Neurosci. 2009 Aug;63(4):529-37. Epub 2009 May 22. Pubmed
  3. Tadori Y, Forbes RA, McQuade RD, Kikuchi T: Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008 Nov 12;597(1-3):27-33. Epub 2008 Sep 20. Pubmed
  4. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY: Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology. 2005 Dec;30(12):2283-9. Pubmed
  5. Malmberg, Mikaels, Mohell N: Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5’—gamma-thio-triphosphate—35S- binding. J Pharmacol Exp Ther. 1998 Apr;285(1):119-26. Pubmed

Enzymes

1. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Tateishi T, Watanabe M, Kumai T, Tanaka M, Moriya H, Yamaguchi S, Satoh T, Kobayashi S: CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2000 Nov 3;67(24):2913-20. Pubmed

2. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression] Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Pubmed
  2. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. Pubmed
  3. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  4. Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM: Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9. Pubmed

4. Cytochrome P450 3A5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 3A7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

6. Carbonyl reductase [NADPH] 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Carbonyl reductase [NADPH] 1 P16152 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

7. UDP-glucuronosyltransferase 1-9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-9 O60656 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

8. Cytochrome P450 1A1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A1 P04798 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

9. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

10. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. Pubmed
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. Pubmed
  3. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 08, 2013 14:23